Researchers in the United States have identified a second gene that is linked with the amyloid plaque deposits found in the brains of Alzheimer's disease patients.
In their study that combine genetic data with brain imaging, they have not only identified the APOE gene-long associated with development of Alzheimer's-but also uncovered an association with a second gene, called BCHE.
The study, led by scientists at the Indiana University School of Medicine, is believed to be the first genome-wide association study of plaque deposits using a specialized PET scan tracer that binds to amyloid.
"The findings could recharge research efforts studying the molecular pathways contributing to amyloid deposits in the brain as Alzheimer's disease develops and affects learning and memory," said Vijay K. Ramanan, the paper's first author and an M.D./Ph.D. student at the IU School of Medicine.
The BCHE gene finding "brings together two of the major hypotheses about the development of Alzheimer's disease," said Andrew J. Saykin, Psy.D., Raymond C. Beeler Professor of Radiology and Imaging Sciences at IU and principal investigator for the genetics core of the Alzheimer's Disease Neuroimaging Initiative.
Scientists have long pointed to the loss of an important brain neurotransmitter, acetylcholine, which is depleted early in the development of the disease, as a key aspect of the loss of memory related neurons.
The BCHE gene is responsible for an enzyme that breaks down acetylcholine in the brain. The other major Alzheimer's hypothesis holds that the development of the amyloid plaques is the primary cause of the disease's debilitating symptoms. As it turns out, the enzyme for which the BCHE gene codes is also found in significant quantities in those plaques.
"This study is connecting two of the biggest Alzheimer's dots," said Dr. Saykin, director of the Indiana Alzheimer Disease Center and the IU Center for Neuroimaging at the IU Health Neuroscience Center.
"The finding that BCHE gene variant predicts the extent of plaque deposit in PET scans among people at risk for Alzheimer's disease is likely to reinvigorate research into drugs that could modify the disease by affecting the BCHE enzyme or its metabolic pathway," he said.
Some existing drugs inhibit this enzyme, but it is unclear whether this influences plaque deposits.
Overall, the results appear to offer scientists new potential targets for drugs to slow, reverse or even prevent the disease.
The results were reported in an article in Molecular Psychiatry.